glp-1 receptor agonists should be avoided in patients with are transforming diabetes care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk when used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are Dietary intake by patients taking
Description
53 This technology has led to the accurate demonstration of ICP lowering both with single dosing and with repeated dosing
doi: 10.1038/ijo.2015.172 17 DeaconCFHolstJJ
It would also be informative to compare GLP-1 RAs head-to-head with acetazolamide
[DOI] [PMC free article] [PubMed] [Google Scholar] 54
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
LEADER Steering Committee on behalf of the LEADER Trial Investigators
